Invention Grant
- Patent Title: Anti-GITR antibodies and methods of use thereof
-
Application No.: US16175453Application Date: 2018-10-30
-
Publication No.: US10280226B2Publication Date: 2019-05-07
- Inventor: Volker Seibert , Olivier Léger , Marc Van Dijk , Taha Merghoub , David Schaer , Gerd Ritter , Takemasa Tsuji
- Applicant: Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
- Applicant Address: US MA Lexington US NY New York CH Zurich
- Assignee: Agenus Inc.,Memorial Sloan-Kettering Cancer Center,Ludwig Institute for Cancer Research Ltd
- Current Assignee: Agenus Inc.,Memorial Sloan-Kettering Cancer Center,Ludwig Institute for Cancer Research Ltd
- Current Assignee Address: US MA Lexington US NY New York CH Zurich
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/00 ; A61K35/17 ; G01N33/50

Abstract:
The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
Public/Granted literature
- US20190062446A1 Anti-GITR Antibodies and Methods of Use Thereof Public/Granted day:2019-02-28
Information query